Arthur M. Brown
Keine laufenden Positionen mehr
Profil
Arthur M.
Brown has founded two companies, ChanTest Corp.
in 1998 and Laguna Pharmaceuticals, Inc. in 2006.
At ChanTest Corp., he held the title of President & Chief Executive Officer, and at Laguna Pharmaceuticals, Inc., he held the title of Chief Executive Officer.
Ehemalige bekannte Positionen von Arthur M. Brown
| Unternehmen | Position | Ende |
|---|---|---|
Laguna Pharmaceuticals, Inc.
 Laguna Pharmaceuticals, Inc. BiotechnologyHealth Technology Laguna Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. Its lead product, Vanoxerine is a therapeutic candidate being developed for treatment of atrial fibrillation and atrial flutter. The firm’s product is a potential pharmaceutical option to rapidly terminate atrial fibrillation in both hospital and home settings. The company was founded in 2006 by Arthur M. Brown and Howard C. Dittrich and is headquartered in Cleveland, OH. | Vorstandsvorsitzender | - |
ChanTest Corp.
 ChanTest Corp. Miscellaneous Commercial ServicesCommercial Services ChanTest Corp. provided testing and discovery services to pharmaceutical and biotech companies. Its services included safety, discovery, cell biology and transporters. The company was founded by Arthur M. Brown in 1998 and was headquartered in Cleveland, OH. | Vorstandsvorsitzender | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
ChanTest Corp.
ChanTest Corp. Miscellaneous Commercial ServicesCommercial Services ChanTest Corp. provided testing and discovery services to pharmaceutical and biotech companies. Its services included safety, discovery, cell biology and transporters. The company was founded by Arthur M. Brown in 1998 and was headquartered in Cleveland, OH. | Commercial Services |
Laguna Pharmaceuticals, Inc.
Laguna Pharmaceuticals, Inc. BiotechnologyHealth Technology Laguna Pharmaceuticals, Inc. develops and manufactures biopharmaceutical products. Its lead product, Vanoxerine is a therapeutic candidate being developed for treatment of atrial fibrillation and atrial flutter. The firm’s product is a potential pharmaceutical option to rapidly terminate atrial fibrillation in both hospital and home settings. The company was founded in 2006 by Arthur M. Brown and Howard C. Dittrich and is headquartered in Cleveland, OH. | Health Technology |
